Industry hopes to build on recent successes of monoclonal antibodies in oncology and inflammatory disease. But evidence is mounting that the exquisite selectivity and binding capacity of these therapeutics can have unwanted side effects, particularly in autoimmune disease. Christopher Thomas Scott investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Berger, J.R. & Koralnik, I.J. N. Engl. J. Med. 353, 414–416 (2005).
Sheridan, C. Nat. Rev. Drug Discov. 4, 357–358 (2005).
Ozcelik, C. et al. Proc. Natl. Acad. Sci. USA 99, 8880–8885 (2002).
Phan, G.Q. et al. Proc. Natl. Acad. Sci. USA 100, 8372–8377 (2003).
Steinman, L. Nat. Rev. Drug Discov., 4, 510–519 (2005).
Yednock, T. et al. Nature 356, 63–66 (1992)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scott, C. The problem with potency. Nat Biotechnol 23, 1037–1039 (2005). https://doi.org/10.1038/nbt0905-1037
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0905-1037
This article is cited by
-
Patterns of technological innovation in biotech
Nature Biotechnology (2012)
-
Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV
Cancer Gene Therapy (2009)
-
Immunotherapy of autoimmunity and cancer: the penalty for success
Nature Reviews Immunology (2008)
-
Mice with a human touch
Nature Biotechnology (2007)
-
Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants: an overview
Transgenic Research (2007)
